Broad Spectrum Coverage – The Rational Choice
Broad-spectrum activity against Gram-positive & Gram-negative bacteria*
Respiratory tract infections (e.g., pneumonia, bronchitis)
Sinusitis, tonsillitis, pharyngitis
Urinary tract infections (UTIs)
Skin and soft tissue infections
Lyme disease (early stage)
Otitis media
Stable against beta-lactamases**
Cefuroxime is the most active of the cephalosporins
against beta-lactamase producing strains**
Superior efficacy with fewer GI adverse events****
Significantly lower incidence of drug related adverse events compared with Amoxiclav (37% vs 16%; P< 0.001), especially GI adverse events (34% vs 12%; P < 0.001)*****
Well-tolerated with a proven safety profile******
* Antimicrob Agents Chemother. 1976 Mar;9(3):511-9; ** Drugs .1979 Apr;17(4):233-66; *** Drugs 61(10):1455-500;
***** Clinical Therapeutics Volume 17, Issue 5, September–October 1995, Pages 838-851;
